ClinicalTrials.gg
RecruitingNCT06888960Updated Sep 17, 2025

Safety Study of CC312 in Autoimmune Disease Patients

An Early Phase 1 interventional study of CC312 in Systemic Lupus Erythematosus (SLE), Idiopathic Inflammatory Myopathy (IIM) and Systemic Sclerosis (SSc), sponsored by CytoCares Inc. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-17.

Sponsored by CytoCares Inc · Early Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Nov 2024; still recruiting 2 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
18
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 266 studies in Lupus Erythematosus, Systemic with a site in China — 168 open to participants now, 191 under way, 22 of them phase 3. Lupus Erythematosus, Systemic · China.

Planned enrollment
169th of 245
18 · median 36
Started
2024
with 42 others
Phase 1
109 of 266
85 open now
Primary completion
2026-11
later than 67 of 190 live
Registered
153rd of 266
by date

Among the 266 studies in Lupus Erythematosus, Systemic with a site in China, this one is the 169th largest by planned enrollment of the 245 interventional ones that give a count, is one of 43 that started in 2024, is one of 109 in phase 1, reaches primary completion later than 67 of the 190 other live ones, and was the 153rd registered.

Lupus Erythematosus, Systemic

1,211 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

168 of the 266 studies in Lupus Erythematosus, Systemic with a site in China are open now. Recruiting first, the newest first:

163 more — sign in →

All 168 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 94 (33%) set no upper age limit and 160 (56%) stop at 75 or younger; 54 take children under 18; 32 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 266 studies in Lupus Erythematosus, Systemic with a site in China, or all of them as a file.
02

Study summary

This study is an open-label, multiple-dose escalation, Investigator-Initiated Trial (IIT) clinical trial designed to evaluate the safety and tolerability of CC312 in adult patients with relapsed and refractory autoimmune diseases. The trial also assesses pharmacokinetics (PK) and preliminary efficacy.

CC312 is a trispecific T cell engager (TriTE) that targets the B cell surface antigen CD19, the T cell antigen CD3, and the T cell co-stimulatory molecule CD28. Given its mechanism of action, which is similar to the "biopharmaceutical version" of CAR-T, there is a higher risk of cytokine release syndrome (CRS) at the onset of infusion administration. Therefore, a lower priming dose will be administered before the therapeutic dosing phase to mitigate this risk and ensure safety, followed by a therapeutic dose to achieve and maintain efficacy.

The study is divided into three dose groups, with 3-6 subjects enrolled in each group, resulting in a total of 9-18 subjects in the study. A "3+3" dose escalation design is employed to systematically evaluate the safety and determine the optimal dose of CC312.

03

Conditions studied

  • Systemic Lupus Erythematosus (SLE)
  • Idiopathic Inflammatory Myopathy (IIM)
  • Systemic Sclerosis (SSc)
  • Rheumatoid Arthritis (RA)
  • Primary Immune Thrombocytopenia (ITP)
  • Autoimmune Hemolytic Anemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects who fully understand the objectives, nature, methods of the study, and possible adverse reactions, voluntarily participate as subjects, and sign the form (ICF).
  • Age ≥18 years (inclusive, based on the time of signing ICF), male or female.
  • For SLE:

    1. Subjects who are diagnosed with SLE according to the 2019 European League Against Rheumatism (EULAR)/1997 American College of Rheumatology (ACR) diagnostic classification criteria;
    2. SLEDAI-2000 score of ≥ 8 points and at least one BILAG grade A or two BILAG grade B under standard treatment conditions;
    3. Meet one of the following conditions: antinuclear antibody (ANA) determined to be positive during the screening period, or anti-dsDNA antibodies higher than normal levels at screening, or anti-Sm antibodies higher than normal levels at screening;
    4. Before the first dose of the drug, subjects must have received at least one of the following standard treatments for 12 weeks, and the dose must have been stable for at least 30 days (dose reduction is allowed and dose increase is not allowed ). Standard treatment regimen refers to the stable use of any of the following (alone or in combination): a. Antimalarial (hydroxychloroquine) monotherapy; b. Antimalarials in combination with oral (OCS, e.g., prednisone or other hormones at equivalent doses) and/or (including mycophenolate mofetil, cyclophosphamide, leflunomide, methotrexate, tacrolimus, ciclosporin, azathioprine, Tripterygium wilfordii); c. OCS and/or immunosuppressant combination therapy. If the subject is receiving OCS (e.g., prednisone or other hormones at equivalent doses), the following criteria must be met: at screening and during the screening period, the maximum dose of OCS is 30 mg/day of prednisone (or other hormones at equivalent doses); other drugs and traditional Chinese medicines that affect immunity may be continued at the discretion of the investigator.
  • For IIM:

    1. According to the 2017 EULAR/ACR Classification Criteria, diagnosed as possible or definite IIM-possible IIM: with a score of 5.5 points without ; definite IIM: with a score of 6.7 points with biopsy;
    2. Meeting one of the following criteria: During or before the screening period, confirmed to have at least one positive myositis-specific autoantibody (MSA), myositis-associated autoantibody (MAA), or ANA;
    3. Conventional treatment is ineffective or the disease relapses after remission. Conventional treatment is defined as: the use of glucocorticoids (prednisone >1 mg/kg/d or equivalent dose) and/or at least one immunomodulatory drug: such as antimalarial drugs, azathioprine, mycophenolate mofetil, cyclophosphamide, methotrexate, tacrolimus, ciclosporin, and/or biological drug products: such as rituximab and belimumab.
  • For IIM:

    1. Subjects who are diagnosed with SSc according to the 2013 EULAR/ACR diagnostic classification criteria;
    2. Meets one of the following criteria: positive ANA confirmed during or before the screening period, or at least one positive SSc-related antibody profile (such as Scl70, Th/To, RP11/12, U3RNP autoantibodies);
    3. Conventional treatment is ineffective or the disease relapses after remission. Conventional treatment is defined as: using glucocorticoids (prednisone > 0.5 mg/kg/d or equivalent dose) and cyclophosphamide, and any of the following immunomodulatory drugs: such as antimalarial drugs, azathioprine, mycophenolate mofetil, methotrexate, leflunomide, tacrolimus, ciclosporin, and/or biological agents: such as rituximab and belimumab, with a cumulative treatment duration > 6 months.
  • For RA:

    1. Diagnosed with RA according to the 2010 EULAR/ACR diagnostic classification criteria;
    2. Disease Activity Score DAS28-ESR >3.2 (i.e., moderate activity or higher) during the screening period;
    3. Failure after treatment with at least one conventional disease-modifying antirheumatic drug (DMARD) and/or at least one targeted synthetic DMARD (tsDMARD)/biologic DMARD (bDMARD) (defined as no remission after at least 3 months of treatment);
    4. At screening, if the subject is taking prednisone or an equivalent dose of a glucocorticoid, the dose must be ≤10 mg/day and stable for at least 4 weeks before the first dose;
    5. The subject must have discontinued traditional Chinese medicine for the treatment of RA for ≥4 weeks before the first dose;
    6. Other DMARDs, except for methotrexate (MTX) (subjects who have been on routine MTX treatment for 12 weeks before enrollment, with a stable MTX dose for 4 weeks before enrollment), must meet the requirements: discontinuation of conventional synthetic DMARDs (csDMARDs) (including but not limited to sulfasalazine, leflunomide, penicillamine, azathioprine, ciclosporin A, cyclophosphamide, hydroxychloroquine, etc.) and herbal agents (including Tripterygium wilfordii, total glucosides of paeony, sinomenine, etc.) for 4 weeks before the first dose; discontinuation of intra-articular, intramuscular, or intravenous corticosteroids for 4 weeks before the first dose; discontinuation of anakinra and etanercept for 4 weeks before the first dose; discontinuation of adalimumab and infliximab for 8 weeks before the first dose; discontinuation of golimumab, certolizumab pegol, and tocilizumab for 10 weeks before the first dose; discontinuation of abatacept for 12 weeks before the first dose; in addition, stable doses of nonsteroidal anti-inflammatory drugs (NSAIDs) are permitted to be continued.
  • For ITP:

    1. Diagnosed with ITP according to the diagnostic criteria of the Chinese Guideline on the Diagnosis and Management of Adult Primary Immune Thrombocytopenia (2020 Edition);
    2. Ineffective response or relapse after at least one prior treatment regimen (including but not limited to TPO mimetics/agonists, corticosteroids, immunoglobulins, azathioprine, cyclophosphamide, and/or rituximab);
    3. At least 2 count measurements (with an interval of more than 24 hours) from the screening period to before the first dose, with an average platelet count \<30×109/Land no single platelet count>35×109/L;
    4. If receiving standard background therapy for ITP, the dose and frequency of this therapy should be stable for at least 4 weeks (dose change ≤10%) before the first dose.
  • For AIHA:

    1. Diagnosed with AIHA according to the diagnostic criteria of the Chinese Guideline on the Diagnosis and Management of Haemolytic Anaemia (2022 Edition);
    2. Poor response after at least treatment (corticosteroids);
    3. Presence of anaemia-related symptoms during the screening period;
    4. The dose of supportive care must be stable for at least 4 weeks before the first dose.
  • Laboratory test results:

Complete blood count:

  1. SLE, SSc, and IIM: ≥1.0 x109/L, ≥60 g/L, platelets ≥50 x109/L;
  2. RA: Neutrophil count ≥1.5 x109/L, haemoglobin ≥90 g/L, platelets ≥100 x109/L;
  3. ITP: Absolute neutrophil count ≥1.0 x109/L, haemoglobin ≥70 g/L, platelets ≥10 x109/L;
  4. AIHA: Absolute neutrophil count ≥1.0 x109/L, platelets ≥50 x109/L (≥10 x109/L for patients with Evans syndrome and transfusion is permitted).

Liver function: (ALT) and aspartate aminotransferase (AST) \<3 times the (ULN), and total serum ≤1.5×ULN (≤3.0×ULN for Gilbert's syndrome) or if bilirubin abnormality is caused by the study disease, participation is allowed upon investigator's judgment.

Renal function: For RA, ITP, and AIHA: Serum creatinine ≤1.5 times ULN, or calculated >50 mL/min (Cockcroft-Gault formula).

  • (LVEF) ≥50%.
  • Female subjects of must agree to use effective from the screening period until 6 months after the last dose. Additionally, they must agree to refrain from collecting or donating eggs during this period; any male partners of must also agree to use effective contraceptive measures during this period.
  • Male subjects with reproductive potential must agree to use effective contraception from the screening period to 6 months after the last dose, and have no plans for reproduction or sperm donation. During this period, their female partners of childbearing potential must also agree to use effective contraception.

Exclusion criteria

Exclusion Criteria:

  • Subjects who have severe lupus nephritis (defined as urinary protein >6 g/24 h or serum creatinine >2.5 mg/dL or 221 μmol/L), or required treatment of active nephritis with protocol-prohibited drugs, or required hemodialysis or received prednisone ≥100 mg/d or equivalent therapy for ≥14 days within 8 weeks before screening.
  • Subjects who have central nervous system diseases caused by SLE or not caused by SLE within 8 weeks before screening (including but not limited to epilepsy, psychosis, posterior reversible encephalopathy syndrome, cerebrovascular accident, encephalitis, central nervous system vasculitis, etc.).
  • Other types of IIM: inclusion body myositis, diabetic amyotrophy, juvenile myositis; severe muscle injury or myositis causing permanent weakness or cardiac involvement due to non-IIM causes (e.g., stroke).
  • Pulmonary arterial hypertension associated with SSc requiring treatment; or rapidly progressive SSc-related lower gastrointestinal tract (small and large intestine) involvement (requiring parenteral nutrition), active antral vascular ectasia; previous renal crisis caused by SSc.
  • Significant organ transplantation (e.g., heart, lung, kidney, liver) or history of hematopoietic stem cell/bone marrow transplantation.
  • Concomitant presence of two or more immune diseases requiring systemic treatment, if the investigator deems the subject unsuitable for enrollment.
  • IgA deficiency (serum IgA level \<10 mg/dL).
  • Have participated in any other clinical trials (including cell or gene therapy) within 4 weeks before screening or within 5 half-lives of the product (whichever is longer).
  • Have received CAR-T therapy within 6 months before screening.
  • Have received B-cell depleting drug rituximab or equivalent treatments (targeting CD19, CD20, BAFF, etc.) within 1 month before screening, unless it can be demonstrated that B cells have returned to pre-treatment levels or within the normal range.
  • Have received anti-SLE treatments (e.g., Saphnelo) other than standard therapy within 3 months before screening or within 5 half-lives of the investigational product (whichever is longer).
  • Have received a live/attenuated vaccine within 4 weeks before screening or plans to receive a live/attenuated vaccine during the study.
  • Active infection.
  • History of Grade 3-4 ( v5.0) allergic reaction to another monoclonal antibody treatment, or known allergy to any component or of the CC312 drug product (including recombinant proteins, polysorbate 80, etc.); patients with a ≤Grade 3 allergy lasting \<24h may participate in this study after discussion with the investigator.
  • Acknowledgement of or evidence of illicit drug use, drug abuse, or alcoholism.
  • Subjects who have received major surgery within 4 weeks before screening or minor surgery within 2 weeks; wounds must be completely healed (surgical procedures such as catheter placement are not exclusion criteria).
  • History of any of the following cardiovascular diseases within 6 months before screening: Class III or IV heart failure, myocardial infarction, unstable angina, uncontrolled or symptomatic atrial arrhythmia, any ventricular arrhythmia, or other heart disease.
  • Any other serious underlying diseases (e.g., active gastric ulcer, uncontrolled seizures, cerebrovascular events, gastrointestinal bleeding, severe signs and symptoms of coagulation dysfunction, heart diseases), mental illnesses, psychological, familial, or endemic diseases that, in the investigator's judgment, may interfere with the planned staging, treatment, and follow-up; affect subjects; compliance; or expose the subjects to a higher risk of complications.
  • Evidence of concurrent malignant tumors within less than 5 years before screening, excluding adequately treated cervical carcinoma in situ, localized cutaneous squamous cell carcinoma, basal cell carcinoma, localized prostate cancer, ductal carcinoma in situ of the breast, or urothelial carcinoma of stage ≤T1. Subjects with prostate cancer undergoing active surveillance are eligible for this study.
  • Pregnant or breastfeeding women.
  • Subjects with positive results for viral serological tests during the screening period: positive for antibody (HIV-Ab), surface antigen (HBsAg), antibody (HCV-Ab), or Treponema pallidum antibody (TP-Ab).
  • Subjects with active or latent tuberculosis (positive T-SPOT) identified during the screening period.
  • History of splenectomy treatment within 6 months prior to screening.
  • ITP subjects: 1) Secondary immune thrombocytopenia secondary to SLE, chronic lymphocytic leukemia (CLL), immunodeficiency common variable (CVID), or antiphospholipid syndrome (APS); 2) Drug-induced thrombocytopenia; 3) Any bleeding event requiring treatment within 4 weeks prior to screening; 4) Within 2 weeks prior to screening, the subject has continuously used drug therapy that affects function (including but not limited to aspirin, aspirin-containing compounds, clopidogrel, salicylates, and/or NSAIDs) for >3 days; 5) History of any arterial or venous thrombosis (stroke, , myocardial infarction, deep vein thrombosis, or pulmonary embolism), or clinical symptoms and medical history suggestive of thrombophilia; or any of the following: known arrhythmia that increases the risk of thrombotic events (e.g., atrial fibrillation), or interval (QTc) >450 msec; or a history of other coagulation abnormalities.
  • ITP and AIHA subjects: Abnormal (PT), international normalized ratio (INR), and activated partial thromboplastin time (aPTT) that are considered clinically significant by the investigator.
  • Other subjects whom the investigator judges to be unsuitable for this study.
Terms in these criteria, in plain language(29)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
18 participants (estimated)

Study arms

  • Experimental
    CC312

    The patient received CC312 via intravenous administration.

    Biological: CC312

Interventions

  • BiologicalCC312

    After a 28-day screening period, subjects who meet the inclusion and exclusion criteria will be enrolled for baseline assessments and biological sample collection prior to the guided administration period. The guided dose of CC312 will be administered via IV infusion on Day -3, followed by safety and tolerability assessments on the third day after the initial administration (i.e., Day -1). The therapeutic dose of CC312 will be administered via IV infusion on Day 1, with subsequent infusions scheduled on Day 4, Day 8, Day 11, Day 15, Day 18, Day 22, and Day 25. Comprehensive safety and tolerability assessments will be conducted at each of these time points.

06

What researchers measure

Primary outcomes

  1. Dose-limiting toxicity (DLT)

    Hematological DLT is defined as a Grade 4 toxic reaction (excluding lymphopenia) that is not attributable to the underlying disease and persists for more than 29 days. Non-hematological DLT refers to any Grade ≥4 toxicities that may be associated with CC312 treatment, or Grade 3 toxicities that may be associated with CC312 treatment and persist for ≥7 days during the DLT observation period following CC312 infusion.

    Time frame: 2 years

  2. Adverse events (AE)/serious adverse events (SAE)

    All adverse events will be evaluated and graded according to the severity criteria of CTCAE (Common Terminology Criteria for Adverse Events) version 5.0, with the exception of Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS), which will be assessed using the ASTCT (American Society for Transplantation and Cellular Therapy) standard.

    Time frame: 2 years

Secondary outcomes

  1. Maximum Serum Concentration (Cmax) of CC312

    Blood samples will be collected for serum concentration analysis at the following time points: within 1 hour before (0 hour) and 1 hour after the infusion of the initial dose; within 1 hour before (0 hour) and 1 hour after the infusion of the first and second doses in the first and third weeks of the therapeutic dose; within 1 hour before (0 hour) and 1 hour after the infusion of the first dose in the second and fourth weeks of the therapeutic dose; and at the time of early withdrawal/end of study (EOS).

    Time frame: 2 years

  2. Area Under the Concentration-time Curve (AUC) of CC312

    The area under the concentration-time curve (AUC) over the dosing interval of 72 hours was calculated using the linear trapezoidal rule.

    Time frame: 2 years

  3. Minimum Concentration (Cmin) of CC312

    The timing of blood sample collection is consistent with the sampling time for Cmax determination.

    Time frame: 2 years

  4. Counts of peripheral B cells

    Blood samples will be collected for CD19+ and CD20+ B cell subsets analysis: For the priming dose: within 1 hour before (0 hour) and at 1 hour and 24 hours after infusion. For the therapeutic dose in the first week: within 1 hour before (0 hour) and at 1 hour and 24 hours after the first and second doses. At early withdrawal/End of Study (EOS).

    Time frame: 2 years

  5. Cytokine Indicators

    Including but not limited to IL-2, IL-6, IL-10, IFN-γ, TNF-α, etc.

    Time frame: 2 years

  6. Anti-drug Antibodies

    Collect blood samples at specific time points for the analysis of anti-drug antibody (ADA) levels and neutralizing antibody (NAb) levels.

    Time frame: 2 years

  7. Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2000) score

    SLEDAI-2000 score is used to evaluate the clinical symptoms and disease activity of SLE. The score ranges from 0 to 15, with higher scores indicating more severe disease activity.

    Time frame: 2 years

  8. Total Improvement Score (TIS)

    The Total Improvement Score (TIS) for idiopathic inflammatory myopathies (IIM) is a validated composite endpoint (typically ranging from 0 to 100) that quantifies the magnitude of overall clinical improvement, with higher scores denoting greater response and lower baseline scores often reflecting more severe disease activity.

    Time frame: 2 years

  9. ACR 20/50 score

    ACR20/50 scores are standardized measures of treatment response in rheumatoid arthritis (RA) that directly correlate with reductions in disease activity. ACR20 represents the minimum clinically meaningful response in RA, while ACR50 indicates a robust response that is strongly associated with significant reduction in disease activity and improved long-term outcomes.

    Time frame: 2 years

  10. Overall Response Rate (ORR) for primary immune thrombocytopenia (ITP)

    Overall Response Rate (ORR): proportion of ITP subjects whose efficacy is assessed as Complete Response (CR) or Response (R) at 4/8/12 weeks after the first infusion (treatment dose).

    Time frame: 2 years

  11. Overall Response Rate (ORR) for Autoimmune Haemolytic Anaemia (AIHA)

    Overall Response Rate (ORR): proportion of subjects whose efficacy is assessed as CR or R at 4/8/12 weeks after the first infusion (treatment dose).

    Time frame: 2 years

  12. Peripheral blood mononuclear cell (PBMC) transcriptome analysis

    Collect peripheral blood at baseline and specific post-treatment time points, isolate peripheral blood mononuclear cells (PBMCs), and decode the global gene expression profiles of immune cells.

    Time frame: 2 years

  13. Single-cell RNA sequencing (scRNA-seq) of peripheral blood mononuclear cells (PBMCs)

    Peripheral blood is collected at baseline and specific post-treatment time points, followed by PBMC isolation and single-cell sequencing to resolve immune cell heterogeneity, uncover dynamic changes in cell states, and decipher cell-cell communication mechanisms.

    Time frame: 2 years

  14. Bone Marrow Lymphocyte Subtype Analysis

    Collect bone marrow samples at baseline and specific post-treatment time points to analyze the proportion and counts of each immune cell subsets.

    Time frame: 2 years

  15. B-cell depletion analysis in lymph nodes

    To evaluate the drug-induced deep depletion of B cells, lymph node samples are collected at baseline and specific post-dose time points to quantify the percentage and count of B cells within the tissue.

    Time frame: 2 years

07

Study locations

1 of 1 sites recruiting
  • Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences
    Tianjin, China 300030, China
    Recruiting
    • Junyuan Qi · Contactqijy@ihcams.ac.cn · 022-23909095
    • Junyuan Qi · Principal investigator
08

References and documents

Publications

  • Murimi-Worstell IB, Lin DH, Kan H, Tierce J, Wang X, Nab H, Desta B, Alexander GC, Hammond ER. Healthcare Utilization and Costs of Systemic Lupus Erythematosus by Disease Severity in the United States. J Rheumatol. 2021 Mar;48(3):385-393. doi: 10.3899/jrheum.191187. Epub 2020 Jul 1. PubMed 32611669 ↗
  • Fortuna G, Brennan MT. Systemic lupus erythematosus: epidemiology, pathophysiology, manifestations, and management. Dent Clin North Am. 2013 Oct;57(4):631-55. doi: 10.1016/j.cden.2013.06.003. PubMed 24034070 ↗
  • Cooper GS, Bynum ML, Somers EC. Recent insights in the epidemiology of autoimmune diseases: improved prevalence estimates and understanding of clustering of diseases. J Autoimmun. 2009 Nov-Dec;33(3-4):197-207. doi: 10.1016/j.jaut.2009.09.008. Epub 2009 Oct 9. PubMed 19819109 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Nov 2026, 24 months after the start.

Of 108 industry-sponsored phase 1 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 35. This study's planned 24 months is below that.

Counting every sponsor, half of 147 studies reached it within 28 months; a quarter within 16 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 20, 2025
First posted
Mar 21, 2025
StartActual
Nov 8, 2024
Primary completionEst.
Nov 8, 2026
CompletionEst.
Nov 8, 2026
Last update
Sep 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06888960
Lead sponsor
CytoCares Inc
Responsible party
Sponsor
First posted
Mar 21, 2025
Start date
Nov 8, 2024
Primary completion
Nov 8, 2026 (estimated)
Completion
Nov 8, 2026 (estimated)
Last update
Sep 17, 2025

Study contacts

CEO
Contact
yingfeng.huang@cytocares.com
021-50582090

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anti-CD19/Anti-CD3/Anti-CD28 Trispecific Antibody CC312

Start the discussion